Sensitivity analysis of risk of cholecystectomy associated with menopausal hormone therapy restricted to women exposed to only one type of regimen
| Variable | No. of women* | No. who had cholecystectomy* | Multivariate HR† (95% CI) |
|---|---|---|---|
| Never used menopausal hormone therapy | 18 694 | 824 | 1.00 (ref) |
| Oral estradiol alone | 277 | 20 | 1.83 (1.18–2.86)‡ |
| Oral estradiol with progestagen | 5 930 | 232 | 1.18 (0.89–1.55) |
| Oral equine estrogen alone | 157 | 17 | 1.90 (1.17–2.11)§ |
| Oral equine estrogen with progestagen | 91 | 10 | 1.64 (0.88–3.06) |
| Transdermal estrogen alone | 2 166 | 101 | 1.20 (0.97–1.47)¶ |
| Transdermal estrogen with progestagen | 15 481 | 674 | 1.05 (0.95–1.16) |
| Other estrogen | 1 552 | 38 | 0.93 (0.67–1.29) |
Note: CI = confidence interval, HR = hazard ratio, ref = reference group.
↵* Data on use of menopausal hormone therapy were missing for 6 250 women, including 211 who reported undergoing cholecystectomy during follow-up.
↵† Adjusted for body mass index, parity, hypercholesterolemia, diabetes and educational level.
↵‡ p = 0.06 for comparison of oral estradiol alone v. oral estradiol with progestagen; p = 0.9 for comparison of oral estradiol alone v. oral equine estrogen alone; p = 0.08 for comparison of oral estradiol alone v. oral transdermal estrogen alone; p = 0.02 for comparison of oral estradiol alone v. other estrogen.
↵§ p = 0.7 for comparison of oral equine estrogen alone v. oral equine estrogen with progestagen.
↵¶ p = 0.3 for comparison of transdermal estrogen alone v. transdermal estrogen with progestagen.